Eli Lilly's Orforglipron (Foundayo) Gets FDA Approval as a $149/Month Pill — Now Shown to Preserve Weight Loss After Stopping GLP-1 Injections

What Just Happened

Eli Lilly got FDA approval for Foundayo (orforglipron) on April 1, 2026 — a once-daily GLP-1 pill for obesity and overweight adults with weight-related health problems, according to Eli Lilly's investor press release.

The approval involved two separate developments. The FDA greenlit the drug for weight loss based on efficacy data from Lilly's ATTAIN-1 trial. Simultaneously, a separate clinical trial published in Nature Medicine demonstrated that orforglipron could function as a maintenance drug for patients switching from injectable GLP-1s like Wegovy or Mounjaro.

The New Numbers

The FDA approval data from Lilly's ATTAIN-1 trial shows patients on the highest dose lost an average of 27.3 pounds (12.4%) of body weight, compared to 2.2 pounds on placebo. Patients who dropped out early still averaged 25 pounds lost, per Lilly's press release.

The maintenance study tracked 376 Americans who had already been on GLP-1 injections (tirzepatide or semaglutide) for at least 72 weeks, according to BBC News. They stopped the jabs and switched to either orforglipron or a placebo pill for one year.

The maintenance data showed:

• Former tirzepatide (Mounjaro) users on orforglipron kept 74.7% of their prior weight loss. The placebo group kept 49.2%.
• Former semaglutide (Wegovy) users on orforglipron kept 79.3% of their prior weight loss. The placebo group kept 37.6%.

The difference between treatment and placebo groups was substantial, though patients on orforglipron did not maintain 100% of their previous weight loss.

Coverage and Important Caveats

BBC News led with the pill as a general obesity treatment and buried the maintenance-trial distinction. The Independent flagged the study's specific framing but downplayed a critical issue: this study was funded by Eli Lilly, the same company selling the drug.

Industry-funded trials are common and often rigorous, but the funding source warrants clear disclosure rather than a footnote. Neither outlet emphasized that the maintenance trial involved only 376 people over one year — a relatively small sample and short window for a drug that patients may need to take indefinitely.

The Pricing Picture

Lilly's press release lists Foundayo at $149/month for self-pay and $25/month with commercial insurance coverage through LillyDirect with free home delivery. Prescriptions started being accepted immediately after approval, with shipping beginning April 6, 2026.

Injectable GLP-1s like Wegovy run over $1,000/month without coverage, according to BBC News. The $149 self-pay price represents a significant reduction.

However, $149/month amounts to $1,788/year out of pocket for people without commercial coverage. That includes many of those who need it most — the uninsured, underinsured, or those relying on government programs where coverage remains uncertain.

Dr. Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, noted orforglipron is "significantly cheaper to manufacture" than current injectables, per the Independent. That cost advantage could theoretically hold prices down long-term, though actual pricing depends on market competition.

Dosing Advantages

Foundayo can be taken any time of day, without food or water restrictions — a distinction Lilly emphasizes and one not shared by other GLP-1 pills.

Novo Nordisk's oral semaglutide (Rybelsus) requires patients to take it on an empty stomach, wait 30 minutes before eating, and swallow with a small sip of water. Foundayo eliminates that requirement.

For people managing busy schedules, travel, or irregular meal timing, the simpler dosing represents a tangible quality-of-life difference. Dr. Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, cited this advantage in Lilly's press release.

The Durability Question

Dr. Marie Spreckley, a weight management researcher at the University of Cambridge, told BBC News: "We still do not know how durable these effects will be over longer periods of time."

The maintenance trial ran one year. Obesity treatment spans years or decades, not months. Long-term data on whether patients need to stay on orforglipron permanently, whether effectiveness fades over time, or what the five-year safety profile looks like remains unknown.

Dr. Cork also noted that while oral drugs cost less to manufacture, "they do not tend to produce the same level of weight loss seen with" injectables. That tradeoff between convenience and cost versus maximum efficacy is real and worth stating clearly.

What's Clear and What Isn't

FDA approval of Foundayo could expand access to GLP-1 therapy for millions who couldn't afford or tolerate injections. The maintenance-trial data provides useful information for people who have been on injections for years and want an alternative that doesn't result in complete weight regain.

The limitations deserve equal attention: a one-year study, funded by the manufacturer, conducted on 376 people. It represents a promising data point but not a proven long-term solution. Longer follow-up studies will be needed to answer the durability questions that currently remain unanswered.